Pharma Journalist -

Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced that the National…
Read More...

SMi Group Reports: In the lead up to the 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference, taking place on 10th-11th May 2021, Justin Mason-Home, HPAPI…
Read More...

Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the…
Read More...

Eli Lilly and Company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a…
Read More...

Provention Bio, Inc. a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a…
Read More...

Altimmune, Inc. a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND)…
Read More...

SMi Reports: There will be a workshop on ‘Developing Apps for Connected Drug Delivery Devices- a practical and integrated HF approach SMi is proud to present the Injectable Drug…
Read More...

Harnessing the activation of innate immunity has become the forefront of new cancer immunotherapies. Only this month SQZ Biotech received FDA clearance for an IND on a cell therapy…
Read More...

Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel antagonist antibodies for cancer and other diseases, and BeiGene, Ltd. announced that they…
Read More...

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a binding agreement to expand their existing collaboration to include the research and development of new…
Read More...